Stock market today: S&P 500 climbs as health care, tech gain; Nvidia earnings loom
Regulus Therapeutics Inc . (NASDAQ:RGLS) stock has reached a new 52-week low, touching down at $1.16. This latest price movement reflects a continued downtrend for the biopharmaceutical company, which has experienced a 1-year change decrease of -6.75%. InvestingPro analysis suggests the stock is currently trading below its Fair Value, with analyst price targets ranging from $3 to $28. Investors are closely monitoring the company’s performance, as reaching a 52-week low often prompts a deeper analysis of a company’s fundamentals and potential future direction. With a market capitalization of $76.64 million, Regulus Therapeutics maintains a strong liquidity position with a current ratio of 14.14 and more cash than debt on its balance sheet. The company, which specializes in the discovery and development of innovative medicines targeting microRNAs, is facing the challenges of a competitive market and the high costs associated with drug development. InvestingPro subscribers can access 10+ additional insights about RGLS’s financial health and future prospects. The company’s stock performance over the past year indicates investor caution amidst these challenges.
In other recent news, Regulus Therapeutics has been the focus of several analysts’ attention. Jones Trading has reiterated its Buy rating on Regulus, anticipating pivotal study and fixed-dose data in 2025. The firm’s analysis was based on a discussion with Regulus’ CEO and President during the Virtual Genetic Medicine Day, centering on the company’s clinical candidate RGLS8429, developed for autosomal dominant polycystic kidney disease (ADPKD).
In addition, Regulus has secured an exclusive license from The University of Texas System for patents and technology aimed at treating ADPKD. The company has also completed patient enrollment for a Phase 1b study of RGLS8429, with topline data expected in 2025.
Furthermore, analyst firms H.C. Wainwright and Canaccord Genuity have both maintained Buy ratings on Regulus, reflecting confidence in the company’s ongoing projects. The company is preparing for an end-of-Phase 1 meeting with the FDA, anticipated to finalize the design for a pivotal Phase 2/3 trial in 2025.
Lastly, the company disclosed additional exploratory results from its Phase 1b study of RGLS8429, which impacted the height-adjusted total kidney volume across high-risk classes. These recent developments highlight the progress of Regulus Therapeutics’ ongoing clinical efforts.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.